IL6 and myelofibrosis: Selinexor has also been shown to reduce the plasma levels of many key pro-inflammatory cytokines (e.g., IL-6, TGFβ, IL-1β, IL-10, IFN-γ, TNF-α) in patients with myelofibrosis [22], and also in ex vivo studies with PBMCs [23].